<DOC>
	<DOCNO>NCT00719394</DOCNO>
	<brief_summary>This first-in-human study GSI-136 , gamma-secretase inhibitor develop treatment Alzheimer disease . This study take place Japan provide initial assessment safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) GSI-136 administration ascend single oral dos healthy Japanese male subject healthy Japanese elderly male subject .</brief_summary>
	<brief_title>Study Evaluating Safety GSI 136 Young Elderly Japanese Males</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion Criteria . 1 . Men age 20 45 year , great 65 year , inclusive , screen agree use medically acceptable form contraception study continue use 12 week test article administration . 2 . Healthy determine investigator basis medical history , physical examination , clinical laboratory test , vital sign measurement 12lead electrocardiogram ( ECG ) . Exclusion Criteria 1 . Presence history disorder may prevent successful completion study . 2 . Any history presence chronic respiratory disorder disease include limited asthma , sleep apnea , chronic obstructive pulmonary disease ( COPD ) .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>alzheimer Disease</keyword>
</DOC>